James Flynn Biography and Net Worth



James Flynn is the Director of Larimar Therapeutics.

What is James E. Flynn's net worth?

The estimated net worth of James E. Flynn is at least $12.40 million as of November 11th, 2024. Flynn owns 5,274,735 shares of Larimar Therapeutics stock worth more than $12,395,627 as of March 29th. This net worth evaluation does not reflect any other assets that Flynn may own. Learn More about James E. Flynn's net worth.

How do I contact James E. Flynn?

The corporate mailing address for Flynn and other Larimar Therapeutics executives is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. Larimar Therapeutics can also be reached via phone at (844) 511-9056 and via email at investors@larimartx.com. Learn More on James E. Flynn's contact information.

Has James E. Flynn been buying or selling shares of Larimar Therapeutics?

James E. Flynn has not been actively trading shares of Larimar Therapeutics during the past quarter. Most recently, on Friday, February 16th, James E. Flynn bought 4,290,617 shares of Larimar Therapeutics stock. The stock was acquired at an average cost of $8.74 per share, with a total value of $37,499,992.58. Following the completion of the transaction, the director now directly owns 6,151,406 shares of the company's stock, valued at $53,763,288.44. Learn More on James E. Flynn's trading history.

James E. Flynn Insider Trading History at Larimar Therapeutics

See Full Table

James E. Flynn Buying and Selling Activity at Larimar Therapeutics

This chart shows James E Flynn's buying and selling at Larimar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Larimar Therapeutics Company Overview

Larimar Therapeutics logo
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Read More

Today's Range

Now: $2.35
Low: $2.25
High: $2.37

50 Day Range

MA: $3.08
Low: $2.25
High: $3.97

2 Week Range

Now: $2.35
Low: $2.19
High: $11.20

Volume

986,346 shs

Average Volume

645,138 shs

Market Capitalization

$149.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99